Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia

Clinica Chimica Acta

Volumn 413, Issue 5-6, 2012, Pages 630-635

  Lee, Yuan Ti ^a,b   Chen, Shiuan Chih ^a,b   Shyu, Ling Yuh ^a   Lee, Meng Chih ^a,b   Wu, Tzu Chin ^a,b   Tsao, Shih Ming ^a,b   Yang, Shun Fa ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cathepsin B; Community acquired pneumonia; Cystatin C; Pneumonia Severity Index

Indexed keywords

C REACTIVE PROTEIN; CATHEPSIN B; CYSTATIN C;

ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CURB 65; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM;

CATHEPSIN B; COMMUNITY-ACQUIRED INFECTIONS; CYSTATIN C; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA;

EID: 84862800271     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.12.010     Document Type: Article

References (39)

1. Health Statistics in Taiwan 2006, Department of Health, Executive Yuan, Republic of China.
2. National Center for Health Statistics. Health, United States, 2006, with chartbook on trends in the health of Americans.
3. Houck P.M., Bratzler D.W., Nsa W., Ma A., Bartlett J.G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164:637-644.
4. Kanwar M., Brar N., Khatib R., Fakih M.G. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics. Chest 2007, 131:1865-1869.
5. Turk V., Kos J., Turk B. Cysteine cathepsins (proteases) - on the main stage of cancer?. Cancer Cell 2004, 5:409-410.
6. Turk B., Stoka V. Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett 2007, 581:2761-2767.
7. Turk B., Turk V. Lysosomes as "suicide bags" in cell death: myth or reality?. J Biol Chem 2009, 284:21783-21787.
8. Joyce J.A., Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 2004, 3:1516-1519.
9. Brix K., Dunkhorst A., Mayer K., Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008, 90:194-207.
10. Johansson A.C., Appelqvist H., Nilsson C., Kågedal K., Roberg K., Öllinger K. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 2010, 15:527-540.
11. Chu S.C., Wang C.P., Chang Y.H., et al. Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clin Chim Acta 2004, 341:133-138.
12. Chen T.Y., Hsieh Y.S., Yang C.C., et al. Relationship between matrix metalloproteinase-2 activity and cystatin C levels in patients with hepatic disease. Clin Biochem 2005, 38:632-638.
13. Tsai H.T., Wang P.H., Tee Y.T., Lin L.Y., Hsieh Y.S., Yang S.F. Imbalanced serum concentration between cathepsin B and cystatin C in patients with pelvic inflammatory disease. Fertil Steril 2009, 91:549-555.
14. Chu S.C., Yang S.F., Tzang B.S., Hsieh Y.S., Lue K.H., Lu K.H. Cathepsin B and cystatin C play an inflammatory role in gouty arthritis of the knee. Clin Chim Acta 2010, 411:1788-1792.
15. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
16. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
17. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
18. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
19. Joyce J.A., Baruch A., Chehade K., et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5:443-453.
20. Vasiljeva O., Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. Biochimie 2008, 90:380-386.
21. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006, 6:764-775.
22. Kollef K.E., Reichley R.M., Micek S.T., Kollef M.H. The modified APACHE II Score outperforms Curb65 Pneumonia Severity Score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest 2008, 133:363-369.
23. Arnold F.W., Brock G.N., Peyrani P., et al. Predictive accuracy of the Pneumonia Severity Index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Respir Med 2010, 104:1736-1743.
24. Cillóniz C., Ewig S., Polverino E., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011, 66:340-346.
25. Richards G., Levy H., Laterre P.F., et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intensive Care Med 2011, 26:34-40.
26. Singanayagam A., Chalmers J.D., Hill A.T. Severity assessment in community-acquired pneumonia: a review. QJM 2009, 102:379-388.
27. Chalmers J.D., Singanayagam A., Akram A.R., et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010, 65:878-883.
28. Müller B., Harbarth S., Stolz D., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:1-10.
29. Niederman M.S., Feldman C., Richards G.A. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006, 27:9-11.
30. Jeong K.Y., Kim K., Kim T.Y., et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J 2011, 28:122-127.
31. Chalmers J.D., Singanayagam A., Hill A.T. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008, 121:219-225.
32. Müller F., Christ-Crain M., Bregenzer T., et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia. Chest 2010, 138:121-129.
33. Stoka V., Turk V., Turk B. Lysosomal cysteine cathepsins: signaling pathways in apoptosis. Biol Chem 2007, 388:555-560.
34. Watzke A., Kosec G., Kindermann M., et al. Selective activity-based probes for cysteine cathepsins. Angew Chem Int Ed Engl 2008, 47:406-409.
35. Turk V., Turk B., Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J 2001, 20(17):4629-4633.
36. Turk D., Guncar G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr 2003, 59:203-213.
37. Turk D., Turk B., Turk V. Papain-like lysosomal cysteine proteases and their inhibitors: drug discovery targets?. Biochem Soc Symp 2003, 15-30.
38. Sébastien Conus, Simon H.U. Cathepsins and their involvement in immune responses. Swiss Med Wkly 2010, 140:w13042.
39. Stoka V., Turk B., Turk V. Lysosomal cysteine proteases: structural features and their role in apoptosis. IUBMB Life 2005, 57:347-353.